Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 21, 2017 16:01 ET | Source: Altimmune, Inc.

Altimmune to Participate in the 10th Annual Biotech Showcase in San Francisco, January 8 – 10, 2018

GAITHERSBURG, Md., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive...
December 21, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune Announces Positive Initial Data from Its HepTcell Phase 1 Study

HepTcell well tolerated in all cohortsInitial data on secondary endpoint demonstrates T cell responses GAITHERSBURG, Md., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a...
December 11, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial

145 Patients to be enrolledData expected in the second quarter of 2018Study will be fully-funded by BARDA GAITHERSBURG, Md., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a...
November 21, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune to Present at the 29th Annual Piper Jaffray Conference

GAITHERSBURG, Md., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, president and chief executive...
November 09, 2017 16:01 ET | Source: Altimmune, Inc.

Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update

Initiated a Phase 2 clinical trial with NasoVAX vaccine with initial data expected in first quarter 2018 Completed enrollment in its Phase 1 HepTcell clinical trial with data expected in fourth...
November 02, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune to Announce Third Quarter 2017 Financial Results on November 9

GAITHERSBURG, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the three...
September 20, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment

60 Patients to be enrolledData expected in the first quarter of 2018 GAITHERSBURG, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company,...
September 19, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune to Provide Corporate Update at the Ladenburg Thalmann 3rd Annual Healthcare Conference

GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive...
September 06, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune to Provide Corporate Update at the Rodman & Renshaw Global Investment Conference

GAITHERSBURG, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive...
August 21, 2017 16:01 ET | Source: Altimmune, Inc.

Altimmune Closes Series B Preferred Stock Offering

GAITHERSBURG, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has closed its offering of approximately 15,656...